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ABSTRACT: To investigate why responses of mast cells to antigen-induced IgE
receptor (FcεRI) aggregation depend nonlinearly on antigen dose, we
characterized a new artificial ligand, DF3, through complementary modeling
and experimentation. This ligand is a stable trimer of peptides derived from
bacteriophage T4 fibritin, each conjugated to a hapten (DNP). We found low and
high doses of DF3 at which degranulation of mast cells sensitized with DNP-
specific IgE is minimal, but ligand-induced receptor aggregation is comparable to
aggregation at an intermediate dose, optimal for degranulation. This finding
makes DF3 an ideal reagent for studying the balance of negative and positive
signaling in the FcεRI pathway. We find that the lipid phosphatase SHIP and the protein tyrosine phosphatase SHP-1 negatively
regulate mast cell degranulation over all doses considered. In contrast, SHP-2 promotes degranulation. With high DF3 doses,
relatively rapid recruitment of SHIP to the plasma membrane may explain the reduced degranulation response. Our results
demonstrate that optimal secretory responses of mast cells depend on the formation of receptor aggregates that promote
sufficient positive signaling by Syk to override phosphatase-mediated negative regulatory signals.
Mast cells and basophils trigger allergic reactions whenpolyvalent antigens cross-link IgE−FcεRI complexes on
the cell surface. Signaling begins with phosphorylation of
FcεRIβ and FcεRIγ subunit ITAMs (immunoreceptor tyrosine-
based activation motifs), which in turn recruit downstream
regulatory proteins for signal propagation and regulation. FcεRI
signaling is a function of the properties of receptor aggregates
formed on the cell surface, including the size, spacing, and rate
of internalization.1−3 Valency is a particularly important factor
controlling signaling efficiency, as summarized in recent
reviews.4,5 Important questions remain to be resolved about
these relationships, particularly regarding the links between
signal regulation and the spatial arrangements of receptor
aggregates after cross-linking. The RBL-2H3 tumor mast cell is
commonly used as a model system, typically by priming cells
with monoclonal IgE specific for a hapten. The best
characterized hapten is 2,4-dinitrophenyl (DNP),6 where cells
sensitized with anti-DNP IgE are activated with ligands such as
DNP-conjugated bovine serum albumin (DNP−BSA) or
ovalbumin. With as many as 25 DNPs per protein carrier,
these multivalent ligands stimulate robust FcεRI signaling.
However, their structural heterogeneity, which arises from
random coupling of DNP to lysine residues, prevents high-
precision control of receptor aggregation. In addition, the
unbound hapten groups of a DNP-conjugated protein are not
equivalent for binding IgE−FcεRI complexes on cell surfaces
because of steric constraints.7,8 Another unknown factor is the
variability in affinity of IgE for haptens arising from the
influence of the hapten’s peptide environment.
To address critical questions regarding the influence of the
aggregation state on FcεRI activation, our first step was the
design of a new DNP-based ligand with defined structure and
valency. As a template, we chose the foldon domain of fibritin
from enterobacteria phage T4, which spontaneously self-
assembles into a stable trimer.9,10 Fibritin trimerization occurs
through β-hairpins in the foldon domain; the foldon trimer is
stabilized by hydrophobic amino acid interactions, intermo-
lecular salt bridges, and hydrogen bonds. We synthesized a
stable trivalent DNP ligand by attaching DNP to the N-
terminus of a peptide comprising the foldon domain via a
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flexible linker and allowing the conjugated peptide to self-
assemble. Structural analysis predicts that each DNP in the
trimer is available to engage with IgEDNP−FcεRI complexes on
the mast cell surface. Optimal doses elicit robust mast cell
responses that are comparable to those achieved with DNP−
BSA and other commonly used DNP-conjugated carrier
proteins. Moreover, degranulation responses of RBL-2H3
cells to DF3 stimulation are characterized by a dose-dependent
bell-shaped curve.
Because bell-shaped secretory response curves are character-
istic of primary mast cells and basophils,11 we focused on the
link between the receptor aggregation state and signaling
outcome. Dose-dependent differences in the DF3−IgE−FcεRI
aggregation state were characterized by equilibrium binding
assays and diffusion measurements. These data provided
parameters for mathematical predictions of receptor aggregate
size in cells stimulated over a range of ligand doses.
Fundamental predictions of the model are the presence of
receptor aggregates at inhibitory doses and dose-dependent
differences in receptor aggregation kinetics. These predictions
were validated by fluorescence-based receptor cluster analysis
and transmission electron microscopy (TEM) imaging. In
addition to characterization of Syk, Lyn, and FcεRI ITAM
phosphorylation, receptor internalization, and calcium mobi-
lization, we focused on phosphatases implicated in FcεRI signal
regulation. We show that the inositol phosphatase SHIP,
previously coined the “gatekeeper” of mast cell degranulation,12
colocalizes with receptors to hold the system in check at both
suboptimal and inhibitory ligand doses. Two closely related
tyrosine phosphatases, SHP-1 and SHP-2, have opposing effects
on mast cell degranulation, suggesting that they act on distinct
substrates. We propose that the ligand-induced aggregation
state is a critical factor for tipping the balance between positive
and negative signaling in the control of mast cell degranulation.
■ RESULTS AND DISCUSSION
Design of a Trivalent Ligand for Cross-Linking DNP-
Specific IgE−FcεRI Complexes. A large body of preexisting
literature supports the concept that antigen−IgE−FcεRI
aggregate size is somehow a key component of mast cell
activation.13 Previous studies characterizing low-valency ligands
have depended on biochemistry techniques, such as gel
filtration chromatography and chemical cross-linking, to
estimate the extent of cross-linking and the size distributions
of ligand−receptor complexes.1,14 Our goal was to reexamine
these questions through use of a new structurally defined
ligand, computation, and experimental measures of aggregation
and signaling.
To create a structurally defined trivalent ligand for inducing
IgEDNP−FcεRI aggregation, a peptide representing the C-
terminus of the T4 fibritin foldon domain was synthesized with
a short peptide linker and DNP conjugated at the N-terminus
(Figure 1A of the Supporting Information). The foldon peptide
self-assembles into a stable trimer in aqueous buffer.15,16 We
refer to this cross-linking reagent as DF3. A fluorescent 5FAM
tag was conjugated to the C-terminus for some applications
(DF35FAM), and the stability of 5FAM-labeled DF3 was verified
(Figure 1B,C of the Supporting Information).
Figure 1A presents a model for the three-dimensional (3D)
atomic structure of DF3. Structural models of IgEDNP−FcεRI
aggregates that may be induced by DF3 (Figure 1B,C) were
constructed on the basis of available structural knowledge, such
as information about the molecular basis for the high-affinity
interaction of IgE with the FcεRIα ectodomain.17 The distance
between two DNP haptens on neighboring arms of DF3 is ∼3.4
nm, although the nine-amino acid linker has sufficient flexibility
such that the center-to-center distance between the two DNPs
may vary between 2.7 and 6.2 nm. Configurations of antigen−
IgE−FcεRI aggregates can become increasingly complex,
because each of the three DNP haptens can engage one arm
of an IgE−FcεRI complex (Figure 1C). The variability in the
distances between Fabs would be expected to increase with the
complexity of the aggregate geometry. We speculate that there
may be a narrow range of distances that allow Lyn, when
anchored on the β subunit ITAM, to mediate trans
phosphorylation of ITAMs in adjacent FcεRI subunits.
Differential spacing may also influence the recruitment or
composition of signaling protein complexes that bind to
phospho-ITAMs, including the enzymes Syk, SHIP, SHP-1,
SHP-2, PI3K, and PLCγ.18,19 These considerations raise the
intriguing possibility that individual receptors within a complex
aggregate may make unequal contributions to FcεRI signaling.
The structural model predicts that bivalent binding of DF3 to
both Fab arms of the same IgE is not possible, which is a
desirable feature shared with other recently developed trivalent
DNP ligands and tetravalent ligands.20 By comparison, DF3 is
more symmetric than published DNA-based ligands14 and
more rigid than PEG-based ligands.21 It is noteworthy that
Figure 1. DF3, a new trivalent ligand for mast cell secretion. (A)
Three monomers self-assemble to produce DF3, in which three DNP
groups (red) attached to the foldon peptide via a flexible linker (cyan)
are symmetrically arrayed. Top and side views are shown. On the basis
of this model, the linker length is ∼10 Å, the distance between any two
DNP groups is ∼34 Å, and the distance between any DNP group and
the center of the trimer is ∼17 Å. (B) Side view of DF3 binding to one
Fab arm (yellow and magenta for light and heavy chains, respectively)
of an IgE−FcεRI α (extracellular domain, blue) complex. (C)
Overhead view of one DF3 bound to three IgE−FcεRI complexes.
(D) Degranulation response in either RBL-2H3 or bone marrow-
derived mast cells, based on the percent of total β-hexosaminidase
released from cells after DF3 stimulation for 30 min. Error bars
represent the standard deviation. Data are representative of three
separate experiments each performed in duplicate.
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structural modeling indicates DF3 also is capable of forming
cyclic receptor dimers (Figure 1C,D of the Supporting
Information). Although cyclic dimers can have limited signaling
potential when engaged by bivalent ligands,22 DF3 may not
have the same limitations because such dimers can be extended
to form larger aggregates.
DF3 Stimulates Mast Cell Secretion. Figure 1D reports
the secretory response of adherent RBL-2H3 cells (hereafter
“RBL cells”) stimulated with DF3 over a wide range of doses.
This ligand induces ∼50% maximal degranulation, a response
that is more robust than the 20−30% responses observed with
DNA- and PEG-based trivalent ligands previously reported.14,21
DF3-stimulated secretion exhibits a bell-shaped curve, which is
also seen for primary cells stimulated with antigen or anti-IgE.23
Murine bone marrow-derived mast cells (BMMCs) also exhibit
dose-dependent secretory responses when challenged with DF3
Figure 2. Computational modeling and experimental characterization of DF3 binding and FcεRI cross-linking. (A) Quality of fit. The solid line is
derived from the model in which each point along the curve corresponds to the calculated number of bound ligands divided by the total number of
IgE antigen-combining sites (two per antibody) at equilibrium for the indicated total ligand concentration. The filled circles correspond to data from
flow cytometric assays of the mean fluorescence of cell-associated DF35FAM. Mean fluorescence measurements (arbitrary units) have each been
divided by a factor F of 227 (arbitrary units). (B) Cumulative probability analysis (CPA) plots of diffusion coefficients derived from SPT
experiments. The mobility is largest for resting receptors (), whereas that of FcεRI cross-linked by 10 nM DF3 (···) is smallest. (C) Computer
simulations predict the fraction of FcεRI in aggregates of specific sizes, determined at steady state after exposure to doses of DF3 ranging from 0.01
to 300 nM. (D) Computer simulations for the kinetics of mean aggregate size over time for 1, 10, and 300 nM DF3. (E) Mean fluorescence intensity
of receptor clusters in cells stimulated with DF35FAM for different time periods. Bars represent the standard error of the mean of two independent
experiments.
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(Figure 1D), thus establishing the applicability of DF3 to
studying physiologically relevant mechanisms. The shift in
optimal DF3 concentration for BMMC secretion is likely due
to ∼8-fold differences in the ligand to receptor ratio utilized in
the BMMC suspension assay.
Modeling DF3 Binding. In addition to molecular scale
computations for estimating ligand−receptor docking, we
adapted the Goldstein−Perelson model24 for FcεRI cross-
linking to provide further insight into aggregation states of
complexes formed after DF3 binding. We obtained a model
that reproduces the dose-dependent binding characteristics of
DF35FAM, measured at equilibrium by flow cytometry (Figure
2A). According to the model, the shape of the binding curve in
Figure 2A is a consequence of the interplay between the
capture of free ligand and receptor cross-linking. At low DF3
concentrations, bound ligands engage multiple receptors, but
most receptors are unbound. At sufficiently high concen-
trations, ligands engage fewer receptors to the detriment of
cross-linking, and receptor binding approaches saturation.
Parameters of the model were determined through fitting.
The structure of our model corresponds closely to that of the
equilibrium continuum model of Goldstein and Perelson24 for
the interaction of a trivalent ligand with a bivalent cell-surface
receptor. The Goldstein−Perelson model, as well as our model,
accounts for all possible acyclic receptor aggregates, but as a
simplification, it omits cyclic aggregates, such as those
illustrated in panels D and E of Figure 1 of the Supporting
Information. Because the quality of fit is excellent (Figure 2A),
extending the model to incorporate cyclic aggregates is not
justified by the available data. However, we did find it necessary
to extend the structure of the Goldstein−Perelson model to
include immobilization of receptor aggregates above a threshold
size (see the Supporting Information). This extension is
consistent with the observed reduction in receptor mobility
upon ligand addition (Figure 2B). It also eliminates the
formation of a gel-like superaggregate, comparable to a “cap”
(i.e., a coalescence of immobile receptors into a localized region
of the cell surface),8 which was not detected experimentally.
This supports the simplifying model assumption that aggregates
containing more than five receptors are not allowed to interact
with each other; free monomers and smaller aggregates may
join by diffusion.
The histograms in Figure 2C show the predicted fractions of
receptors in monomeric and various aggregated states for
different DF3 doses at steady state. As can be seen, for a dose of
either 1 or 300 nM, at which secretory responses are poor
(Figure 1D), at least 90% of the receptors are predicted to be in
clusters. The distribution of receptor aggregate sizes at 1 nM is
similar to that at 10 nM, the optimal DF3 dose for
degranulation. At the supraoptimal dose of 300 nM, aggregates
are smaller on average, but the model still predicts the presence
of aggregates containing more than nine receptors. These
results, which were subsequently confirmed experimentally in
EM experiments (Figure 3), suggest that mast cell activation
does not strictly correlate with receptor aggregation and that
the dose−response curves of Figure 1D are likely shaped by a
balance of positive and negative signaling.
Our model, which was formulated through a rule-based
approach that allows kinetic Monte Carlo simulations
(Supporting Information), can make predictions about the
kinetics of ligand-induced receptor aggregation (Figure 2D of
the Supporting Information). The model predicts that the
initial rate of receptor aggregate formation increases with ligand
dose. However, at sufficiently high doses, receptor aggregation
is transient. This qualitative behavior was confirmed exper-
imentally in fluorescence microscopy experiments (Figure 2E).
Thus, high-dose stimulation of mast cells entails significant
receptor aggregation, even though the level of aggregation at
equilibrium is low. This behavior further suggests that there is
not a simple relationship between aggregation and cell
activation.
Single-Particle Tracking Indicates That DF3 Induces a
Reduction in Receptor Mobility. Previous observations
indicate that diffusion of antigen−IgE−FcεRI complexes is
progressively slowed as receptor aggregates grow in size.25
Aggregates of two or three receptors have been shown to be
nearly as mobile as receptor monomers, whereas larger
aggregates slow and ultimately reach an essentially immobile
state. For DF3, we also observed this deceleration (Figure 2B)
via established single-particle tracking methods.25,26 Quantum
dot (QD)-labeled IgE−FcεRI complexes aggregated with 10
nM DF3 exhibited a marked shift in mobility (Figure 2B).
Cross-linking of QD-labeled IgE−FcεRI complexes with a
supraoptimal concentration of DF3 (300 nM) led to enhanced
receptor slowing. The less dramatic deceleration at the higher
ligand dose suggests a smaller average aggregate size, which is
consistent with model predictions (Figure 2C).
Fluorescence Imaging Reveals DF3 Dose-Dependent
Kinetics of IgE−FcεRI Aggregation. Our model predicts
dose-dependent differences in receptor aggregation kinetics
(Figure 2D), which may correlate with mast cell outcomes. We
sought to experimentally validate the computational results
using quantitative fluorescence analysis of receptor clustering
Figure 3. DF3 induces dose-dependent FcεRI clusters on the cell
surface. (A−C) TEM images of membrane sheets prepared from cells
after the FcεRI had been cross-linked for 5 min with 0, 10, or 300 nM
DF3 and immunogold labeling (6 nm gold) for FcεRI β. Arrows point
to signaling patches, typical after addition of antigen. The bar is 0.1
μm. (D) Plot of mean Hopkins test statistic values. The bar indicates
the group mean, while whiskers represent the entire range of each
group.
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(Figure 2E). Cells were grown on glass coverslips, sensitized
with DNP-specific IgE, and incubated at 37 °C with a
fluorescent ligand (DF35FAM). At defined time intervals, cells
were fixed, mounted on glass slides, and imaged by wide field
microscopy. 3D images were deconvolved to minimize out-of-
focus fluorescence emission and spot intensities analyzed. In
good agreement with model predictions, a high DF3 dose (300
nM) led to a rapid increase in average cluster intensity, which
was followed by a decrease in intensity. The dose optimal for
degranulation (10 nM) elicited a slightly slower increase in
average cluster intensity, which reached a relatively higher level
and then persisted. The suboptimal dose of 1 nM elicited a
markedly slower increase in average cluster intensity, eventually
approaching the maximal intensity stimulated by the optimal
dose. These data are in qualitative agreement with our
simulation results (compare Figure 2D,E; see also Supporting
Information). We note that the experimental time courses for
the 10 and 300 nM cases are closer to each other than the
simulated time courses. Simulations (not shown) indicate that
this observation is to be expected if small aggregates (e.g.,
receptor monomers and dimers) do not contribute to the
measured mean cluster intensity (i.e., are below the threshold
Figure 4. Characterization of upstream and downstream events in response to DF3. (A) Tyrosine phosphorylation kinetics of FcεRI β and γ
subunits measured in anti-FcεRIγ and anti-FcεRIβ immunoprecipitates and Syk346 and Lyn507 phosphorylation kinetics measured in whole cell
lysates. (B) Quantification of blots shown in panel A, where normalized band intensities are plotted vs stimulation time. (C) Fura-2-loaded individual
cells were stimulated with DF3. Ratio intensities (360/385) were measured and converted to [Ca2+] as described in Methods. (D) Internalization of
FcεRI measured by acid stripping of cells sensitized with fluorescent IgE and stimulated with DF3. Confocal images show the increase in internalized
pools of fluorescent IgE over time. The plot illustrates the kinetics of fluorescent IgE−FcεRI endocytosis, as measured by flow cytometry. All data are
representative of at least two independent experiments.
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb500134t | ACS Chem. Biol. 2014, 9, 1508−15191512
of detection). Taken together, it is clear that the antigen dose
strongly influences the kinetics of aggregate formation, as well
as aggregate size. Rapid but transient aggregate formation at
high doses or delayed formation of large aggregates seen in
both simulations and experiments could potentially lead to
distinct patterns of recruitment of both signaling and endocytic
adaptors to FcεRI.
High-Resolution EM Imaging Confirms DF3 Induces
the Formation of FcεRI Signaling Patches. Steady-state
simulations predict that most of the cell’s complement of
300000 receptors could be cross-linked into small and large
aggregates at low or high doses of trivalent ligand that restrict
degranulation. We next used immunoelectron microscopy
methods to characterize the redistribution of FcεRI after
exposure to DF3 at all doses considered. Native membrane
sheets were prepared from resting or stimulated RBL cells,
immunogold-labeled for FcεRIβ, and imaged by TEM.4,27 As
expected on the basis of earlier studies, we observed FcεRI to
be non-randomly distributed in the resting state (Figure 3A).
For resting receptors, clustering is modest, an indicator of
FcεRI proximity, and not indicative of preformed aggregates.
Rather, these small clusters are thought to reflect transient co-
confinement of diffusing receptors in rafts and islands or
corrals.4,25 Images in panels B and C of Figure 3 show that
receptors accumulate in electron-dense regions of the
membrane at both the optimal (10 nM) and inhibitory (300
nM) doses of DF3. An increase in the level of clustering at all
doses of DF3 was confirmed by applying the Hopkins spatial
statistic test to a minimum of 10 images per data set. These
results are summarized in Figure 3D, which indicates that an
increase in the level of receptor clustering is statistically
significant for both optimal (10 nM) and suboptimal (1 and
300 nM) doses.
It is important to emphasize that both fluorescence (Figure
2E) and electron microscopy (Figure 3) methods do not
provide direct measures of aggregation, because increases in
receptor density after activation are likely to reflect nearby
aggregates of various sizes that have coalesced into a “signaling
patch”.4 Thus, the computational model provides complemen-
tary information and arguably a more precise estimate of the
size distribution of receptor aggregates.
DF3 Triggers a Differential, Dose-Dependent Signal
Initiating Phosphorylation Events. Dose-dependent differ-
ences in phosphorylation of proteins that trigger signal
initiation in response to DF3 were evaluated. Lysates were
prepared from RBL cells challenged with either 1, 10, or 300
nM DF3. In Figure 4A, receptor complexes were isolated by
immunoprecipitation using anti-FcεRI γ and β subunit
antibodies, followed by sodium dodecyl sulfate−polyacrylamide
gel electrophoresis (SDS−PAGE) and Western blotting with
pan-reactive anti-phosphotyrosine antibodies or antibodies
against ITAM-bearing β and γ subunits. To evaluate Syk and
Lyn phosphorylation, Western blots were probed with
phospho-specific antibodies. Results are plotted in Figure 4B,
expressed as values normalized to either total protein or β-actin.
Phosphorylation of FcεRI subunits and Syk continues to
increase during stimulation for up to 5 min with the optimal
dose of DF3 (10 nM). Although phosphorylation of both
FcεRI subunits was markedly lower at low (1 nM) and high
DF3 doses (300 nM), when compared to that at the optimal
dose, the decrease in γ phosphorylation was significantly greater
(∼2−3-fold) than that in β phosphorylation. Elevated β
phosphorylation at inhibitory doses most likely is linked to
negative signaling, based on previous studies that show its
increased phosphorylation during inhibitory signaling and
association with negative signaling molecules SHP-1 and
SHIP.28,29 Compared to that at an optimal dose stimulus, Syk
phosphorylation was reduced only ∼2-fold at a high dose but
was ∼7-fold lower after stimulation for 5 min at a low dose. Lyn
dephosphorylation at the inhibitory site Y507 was significantly
reduced upon low-dose stimulation, whereas high-dose
stimulation led to a dephosphorylation rate similar to that
seen with the optimal dose.
Inhibition of Degranulation at Low and High DF3
Doses Correlates with Calcium Responses and Is Not
Due to Enhanced Clearance of Surface Receptors.
Results in Figure 4C show that high and low doses of DF3
induce Ca2+ responses weaker than that elicited by the optimal
dose of DF3. In these experiments, IgE-primed RBL cells were
preloaded with Fura-2 AM, followed by single-cell, ratio
imaging microscopy during antigen challenge. A typical
response to 10 nM DF3 is a rapid spike in the intracellular
calcium concentration followed by an oscillatory sustained
phase. By comparison, calcium responses to 1 or 300 nM DF3
typically exhibited a weak or absent initial spike, followed by
oscillations that return almost to baseline in the intervals.
Because mast cell secretion is calcium-dependent, these results
are consistent with poor degranulation at suboptimal ligand
doses.
Finally, Figure 4D reports results of experiments designed to
test the possibility that low and/or high doses of DF3 might
result in more extensive clearance of receptors from the cell
surface, which could theoretically limit sustained signaling. The
assay is illustrated in the images in Figure 4D, where cells were
sensitized with IgE-Alexa647, incubated with the DF3 ligand at
37 °C to permit internalization, and then briefly exposed to an
acidic wash at 4 °C to strip off surface IgE. The image at the top
left reports levels of red fluorescent IgE bound to resting cells
in the absence of an acid wash. For quantification, identical
samples were processed for flow cytometry, with and without
acid stripping. The results show that, contrary to the possibility
of a greater level of endocytosis at high doses, only ∼15% of
receptors are endocytosed after incubation with 300 nM ligand.
This endocytosis occurs within the first 2 min, followed by
cessation of further internalization. This is consistent with the
model predictions in Figure 2, where continued binding of
excess ligand reduces the size of aggregates but does not ablate
them. By comparison, endocytosis does not slow dramatically
until 10 min at the optimal dose of the trivalent ligand (10 nM
DF3). The lowest dose (1 nM) of the ligand supports
endocytosis for up to 20 min, achieving the highest total level of
internalization at ∼50%. Thus, the lowest dose of ligand, which
is a poor degranulating stimulus, clearly triggers the post-
translational modifications (phosphorylation and ubiquitina-
tion) that are associated with immunoreceptor endocytosis.30
It is notable that other trivalent and bivalent ligands fail to
cause measurable internalization upon FcεRI cross-linking.14,31
This suggests that, in addition to aggregate size, structural
aspects of antigens other than valency are important factors in
endocytosis. These factors remain unknown but could include
the distance between antigen binding sites or the flexibility of
the carrier.
SHIP Colocalizes with Resting and Activated FcεRI,
with Enhanced Kinetics at Inhibitory Doses. The
persistence of substantially sized receptor clusters (which likely
represent groups of aggregates) at inhibitory doses is confirmed
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by our EM studies. On the basis of this observation, we
hypothesized that positive signaling is being counteracted by
negative signaling at these doses, perhaps by the recruitment of
phosphatases. The inositol phosphatase SHIP has been
previously shown to downregulate FcεRI signaling at supra-
optimal antigen concentrations.32 Therefore, we next evaluated
its colocalization with FcεRI under resting and stimulated
conditions. Images in Figure 5 illustrate this protocol, where
membrane sheets were immunogold-labeled using antibodies to
phospho-SHIP (5 nm gold) and FcεRI (10 nm gold) and
imaged by TEM. This high-resolution imaging method reveals
dose-dependent coclustering of phospho-SHIP with FcεRI β.
Figure 5. Dose-dependent role of SHIP in FcεRI signaling. (A) TEM images of membrane sheets prepared from cells after the FcεRI had been
cross-linked for 2 min with indicated doses of DF3 and immunogold labeling for SHIP (6 nm gold) and FcεRI β (12 nm gold). Arrows point to
coclusters of SHIP and FcεRI β. The bar is 0.1 μm. Images are accompanied by their Ripley’s bivariate test results. (B) Gold particles marking SHIP
were scored for coclustering with FcεRI β in membrane sheets from resting cells and cells stimulated for 2 and 5 min. At least 2000 gold particles
were counted for each experimental condition. The asterisk indicates clustering is statistically different between any two doses at 2 min. (C)
Membrane recruitment of phospho-SHIP with the DF3 stimulus. Cells were stimulated, followed by fractionation to yield crude membrane fractions.
Samples were separated by SDS−PAGE and immunoblotted with the anti-phospho-SHIP antibody. (D) Proximity ligation assay confirming the
interaction of phospho-SHIP with the β subunit of FcεRI. The fluorescent signal was measured in RBL-2H3 cells overexpressing chimeric FceRI β
either under basal conditions or by cross-linking the chimeric receptor, and basal or stimulated (10 nM DF3) wild-type RBL-2H3 cells. Results are
representative of two independent experiments. (E) Western blot confirming 60% knockdown of Lyn or 10-fold overexpression of Lyn in RBL-2H3
cells. (F) Proximity ligation assay measuring phospho-SHIP and β interaction in either Lyn knockdown (KD) or Lyn overexpression (O/X) cells
stimulated with 10 nM DF3. Results are representative of two independent experiments. (G) Degranulation response in RBL-2H3 cells with Lyn
KD, based on the percent of total β-hexosaminidase released from cells after stimulation with indicated doses of DF3 for 30 min. Error bars represent
the standard deviation. Results are representative of at least two independent experiments.
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We found that, although the label for phospho-SHIP is
relatively sparse in resting cells, where it is found it is
consistently colocalized with resting FcεRI (arrows, Figure 5A,
left). As the stimulus proceeds, additional phospho-SHIP
accumulates on cell membranes, where it largely colocalizes
with receptor signaling patches (small gold particles, Figure
5A). Remarkably, as shown, the extent of phospho-SHIP
colocalization with FcεRI showed different kinetics for three
doses of DF3. Treatment groups were found to be statistically
different using a one-way analysis of variance (ANOVA) test (p
= 4.54 × 10−8). For both suboptimal (1 nM) and supraoptimal
(300 nM) doses, accumulation of phospho-SHIP was most
notable at 2 min. In contrast, phospho-SHIP colocalization with
receptors at 2 min at the optimal dose was low [10 nM (Figure
5B)], increasing to more significant levels at 5 min.
Biochemical experiments were performed to confirm the
rapid recruitment of phospho-SHIP to the membrane with sub-
and supraoptimal doses of DF3 (Figure 5C). A simple cell
fractionation experiment revealed the presence of phospho-
SHIP at the membrane upon the DF3 stimulus for 2 min with
inhibitory doses, but not with the optimal dose.
It is important to note that both the EM and membrane
fractionation methods strongly indicate the recruitment of
SHIP to receptor signaling patches but do not report the direct
interaction of proteins. In addition to FcεRI subunits,33 SHIP
has several other potential docking partners, including adaptor
Figure 6. Positive and negative regulators of mast cell signaling. (A) Western blot confirming the 75, 90, and 71% knockdown of SHIP, SHP-1, and
SHP-2, respectively. (B) Degranulation response after DF3 stimulation for 30 min in RBL-2H3 cells knocked down for SHIP and SHP-1. (C)
Degranulation response or fold change in secretion in RBL-2H3 cells knocked down for SHIP after stimulation for 10 or 30 min. (D) Degranulation
response after stimulation for 30 min in RBL-2H3 cells knocked down for SHP-2 (C). Degranulation values in panels B−D are based on the percent
of total β-hexosaminidase released from cells after stimulation with the indicated doses of DF3. Error bars represent the standard deviation. Results
are representative of three independent experiments. (E and F) Tyrosine phosphorylation kinetics of Syk346 measured in whole cell lysates from
WT, SHP-1, and SHP-2 KD cells stimulated with 10 nM DF3. Results are representative of three independent experiments. (G) Quantification of
the fluorescent signal from PLA for the Lyn−FcεRI β interaction in WT and SHP-2 KD cells. Bars represent the standard deviation of mean
fluorescent spots counted from at least 80 cells (n), from seven fields of view. Results are representative of two independent experiments.
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proteins such as Shc, Grb2, and Dok.34,35 SHIP can also be
recruited to PI(3,4)P2 via its C2 domain.36 We next used the
proximity ligation assay (PLA) in RBL cells transfected with a
chimeric receptor composed of the extracellular and trans-
membrane domains of the IL-2 α subunit (Tac antigen) joined
to the cytoplasmic domain of the FcεRI β subunit;37 this
construct is termed TTβ. Transfected cells were fixed before or
after TTβ had been cross-linked with anti-Tac antibodies,
permeabilized, and incubated with primary antibodies against
SHIP and FcεRI β that were conjugated with the paired PLA
probes. Following ligation and amplification, fluorescent
oligonucleotide probes were imaged and quantified as spots
by confocal imaging. Results in Figure 5D show that TTβ cross-
linking led to the significant recruitment of SHIP to the
chimeric β receptor, providing evidence that SHIP and β likely
interact or are part of a complex, given their proximity (<40
nm) as detected by PLA.
Figure 5D also shows results of the PLA after cross-linking of
IgE−FcεRI complexes with DF3 in RBL cells. Like the isolated
chimeric β, phospho-SHIP is recruited to the intact receptor
after cross-linking (compare images in basal and simulated wild-
type RBL cells). Because Lyn is principally responsible for β
ITAM phosphorylation37 and also a potential binding partner
for SHIP,34 we also compared results of the PLA in cells
overexpressing Lyn (Lyn O/X in Figure 5F) to results in cells
treated with siRNA to knock down Lyn (Lyn KD in Figure 5F).
Results show that the recruitment of phospho-SHIP to FcεRI β
is strongly dependent on Lyn: the level is dramatically increased
upon Lyn overexpression and significantly reduced upon Lyn
knockdown in RBL cells. Western blots in Figure 5E show the
comparative levels of Lyn in wild-type (WT), Lyn KD, and Lyn
O/X cells. Finally, the link between Lyn and negative regulation
of secretion is illustrated in Figure 5G, where Lyn knockdown
(60%) results in a significant increase in the level of DF3-
stimulated degranulation over a wide range of doses.
It is intriguing to speculate that incomplete ITAM
phosphorylation may be the reason that aggregates induced
at low or supraoptimal doses favor faster SHIP recruitment, but
reduced Syk activity. This hypothesis is based upon the recent
study by Cambier and colleagues, who showed that mono-
phosphorylation of Igα and Igβ ITAMs drive the activation of
SHIP-Dok circuitry to cause anergy in B cells.38 SHIP, with its
single SH2 domain, is favored for recruitment to mono-
phosphorylated ITAMs over Syk, which has two SH2 domains
that interact with dually phosphorylated FcεRI γ ITAM. New
reagents are needed to evaluate the mono- and biphosphor-
ylation status of FcεRI β/γ ITAMs after the DF3 stimulus. This
is an important future direction, because monophosphorylation
is a reasonable mechanism for the conversion of a positive
signaling ITAM to an inhibitory one (ITAMi). The
phenomenon of inhibitory signaling from other FcR has been
described recently, including the formation of “inhibisome”
clusters that also recruit protein phosphatase SHP-1.39
The Dose−Response Curve for Degranulation Is
Differentially Regulated by Protein/Inositol Phospha-
tases. FcεRI signal initiation, including activation of SHIP and
Syk, is regulated by protein tyrosine phosphatases. The closely
related protein tyrosine phosphatases, SHP-1 and SHP-2, have
been described as negative and positive effectors of FcεRI
activation. Although both bind to FcεRI and affect phosphor-
ylation events downstream, no significant changes in mast cell
degranulation have been previously reported.40,41 We assessed
the effect of SHIP, SHP-1, and SHP-2 knockdown on
degranulation responses to a wide range of DF3 doses. The
Western blot in Figure 6A shows that treatment with specific
siRNA for 24 h was optimal for lowering endogenous levels of
SHIP, SHP-1, and SHP-2 by 70−90%. The knockdown of both
SHIP and SHP-1 produced a marked increase in the level of
mast cell degranulation across all doses of DF3 (Figure 6B).
With a 30 min stimulus, results show that the most dramatic
enhancement of degranulation was at the suboptimal dose of 1
nM, with a >6-fold increase in response seen with SHIP KD
and an ∼3-fold increase in response to SHP-1 KD after
stimulation for 30 min.
The kinetics of clustering and internalization were shown
above to differ markedly across suboptimal and supraoptimal
doses. Thus, dose-dependent differences in the kinetics of
degranulation were also evaluated by measuring degranulation
responses after SHIP knockdown and shorter exposures to DF3
(Figure 6C). The fold increase in secretion at 300 nM was
marked in SHIP KD cells with a 10 min stimulus, consistent
with the rapid rise in the recruitment of SHIP to FcεRI
signaling patches at this high dose (Figure 5B).
Inhibition of calcium responses and degranulation by SHIP
has been shown previously,32 consistent with a role for its
substrate PIP3 (phosphatidylinositol-3,4,5-P3) as an allosteric
activator of PLCγ isoforms in mast cells.42 The regulation of
SHIP’s own activity is somewhat ambiguous. We found that
changes in SHIP phosphorylation were modest over all doses of
DF3 (data not shown). This suggests that membrane
recruitment, measured here by TEM and by PLAs, is a critical
readout of SHIP activation. Allosteric regulation of SHIP36
during this recruitment may also play an important role.
Contrary to SHP-1, knockdown of SHP-2 significantly
decreases the degranulation response across all doses (Figure
6D), thus demonstrating its opposing role as a positive
regulator of mast cell responses. Lowering SHP-2 levels led
to a sustained reduction in the level of Syk phosphorylation
(Figure 6E,F) as well as a modest but statistically significant (p
< 0.03) reduction in the level of interaction of Lyn with FcεRI
β (Figure 6G). As discussed further below, these data
underscore the dual roles for Lyn in FcεRI signaling. Lyn is
required to accelerate ITAM phosphorylation for the recruit-
ment and activation of Syk, a step that is influenced by SHP-2.
As a negative regulator, Lyn is critical for recruiting SHIP to
FcεRI and likely linked to SHP-1.
Summary and Conclusions. In this study, we have
characterized a novel trivalent ligand, DF3, which triggers
robust and dose-dependent mast cell responses by efficiently
cross-linking the IgE−FcεRI complexes. The variability in
distance between cross-linked receptors predicted by structural
modeling suggests increased complexity in aggregate geometry
could influence the recruitment of downstream signaling
proteins. Using both experimental and computational ap-
proaches, we characterized dose-dependent receptor aggregate
properties and observed the persistence of large receptor
aggregates even at inhibitory doses. Furthermore, we observe
dose-dependent differences in the kinetics of receptor
aggregation that lead to the equilibrium state. On the basis of
these observations, we hypothesized that reduced mast cell
responses with suboptimal dose stimulation are caused by a
shift in the activation of positive and negative signaling, causing
preferential recruitment of phosphatases over Syk to FcεRI. At
the optimal dose, receptor clusters are capable of overriding
negative signaling by primarily recruiting Syk. Support for this
hypothesis comes from the observation that Syk is weakly
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phosphorylated, whereas the inositol phosphatase SHIP is more
rapidly recruited to the receptor, at inhibitory doses of 1 and
300 nM. This is potentially caused by ITAM monophosphor-
ylation.38
RNAi-mediated studies were performed to characterize the
role of phosphatases SHIP, SHP-1, and SHP-2 in regulating
mast cell responses. Interestingly, in our study, both SHIP and
SHP-1 were shown to negatively regulate degranulation across
all doses. Knockdown of SHP-1 leads to increased Syk
phosphorylation over time. On the other hand, SHP-2
knockdown causes significant reduction in both the degranu-
lation response and Syk phosphorylation. Thus, SHP-1 and
SHP-2 are key phosphatases that tune the secretory response,
potentially by regulating SHIP and Syk signaling loops,
respectively. Our results demonstrate that optimal secretory
responses of mast cells and basophils depend on the formation
of receptor aggregates capable of overriding negative regulatory
signals. Future studies are required to better understand how
different aggregate sizes tip the balance of positive and negative
signaling.
■ METHODS
Additional details about the experimental and computational methods
may be found in the Supporting Information.
DF3 Synthesis and Purification. The trivalent ligand was
synthesized by AnaSpec. Briefly, Fmoc-Lys(5-Mtt)-OH was loaded
onto HMP resin, followed by treatment with 20% piperidine in DMF
to generate H-Lys(Mtt)-HMP resin. Peptide assembly was completed
by sequentially coupling each designated Fmoc-AA(xx)-OH in an
HCTU/NMM/DMF mixture and de-Fmoc using 20% piperdine in
DMF. The resin was split into two portions to produce either the
unmodified (dark) peptide or a variant with a fluorescent (5FAM) tag
at the COOH terminus. After the last Fmoc-Lys(DNP)-OH coupling,
the Mtt protecting group of Lys(Mtt) was removed with a 1% TFA
cocktail and N-teminal Fmoc was removed with 20% piperidine in
DMF. Treatment with cleavage cocktail released the crude peptide,
which was purified by preparative reversed phase high-performance
liquid chromatography and lyophilized.
Degranulation, Western Blotting, Internalization, Mem-
brane Fractionation, and EM Assays. Cell monolayers were
grown in 24-well tissue culture plates for 24 h and sensitized with 5
nM IgEDNP. Measurement of β-hexosaminidase release and immuno-
blotting were performed as described previously.43 Internalization of
IgE−FcεRI complexes was measured by a previously described acid
stripping protocol and flow cytometry.25 Fluorescent images of cells
stimulated with DF35FAM were taken on an inverted Olympus IX71
microscope using a 150× objective lens. Membrane fractionation was
performed as previously described.44 Methods for the preparation of
mast cell membrane sheets and immunogold labeling FcεRI have been
described.27 Digital images were acquired using a Hitachi H600
transmission electron microscope, followed by image processing to
capture the FcεRI gold particle distribution and use of published
methods for statistical analysis of clustering.45 Statistical differences
were also computed using a one-way ANOVA test in MATLAB
(version 8.0.0, The MathWorks).
Flow Cytometry-Based Binding Assays. Suspensions of
sensitized RBL cells (2 × 106 cells/mL) were incubated at room
temperature with DF35FAM at doses ranging from 0.01 to 1000 nM
while the mixture was gently shaken. After 1 h, the mean fluorescence
(520 nm) was measured on a Becton Dickinson FACScan flow
cytometer, controlled with Cell Quest software. The fluorescence of
nonsensitized cells, incubated with a fluorescent ligand under identical
conditions, served as a baseline control for nonspecific binding.
Single-Particle Tracking. Experiments were performed using
functionally monovalent QD-IgE,26,46 and analysis of single-quantum
dot tracking was performed as previously described.46 Diffusion
coefficients (D1−3) were determined by fitting the first three points of
the mean squared displacement (MSD) plots to the equation MSD =
offset + 4D1−3Δt;47 the median D for all trajectories under each
treatment condition is reported, and the distribution of values can be
seen in the cumulative probability analysis plot.
Calcium Measurements. Cells were loaded with Fura-2 AM for
30 min before being washed and observed on an inverted Olympus
IX71 microscope, equipped with a Til Monochromator (TILL
Photonics). Excitation light alternately passed through 10 nm band-
pass filters centered at 350 and 380 nm; emission was collected with a
510 nm WB 40 filter (Omega Optical). Images were acquired with an
Andor iXon EM-CCD camera and reagents added by manual
micropipet. Ratio values for each cell in a field were calculated for
user-defined regions after background subtraction and converted to
[Ca2+] using the Fura-2 calcium imaging calibration kit. Analysis was
performed using ImageJ48 and Prism (GraphPad Software).
Clustering Analysis. Stimulated cells were fixed and imaged with
an inverted Olympus 1X71 instrument (Mercury fluorescence lamp),
with a 150× oil objective. Images were deconvolved using Huygens
Essential software, and the top few slices of each cell were used for
analysis. Roughly 20 cells per treatment group were used for analysis.
Image analysis was performed using a custom script written in
MATLAB (version 8.0.0, The MathWorks).
Proximity Ligation Assays. Cells grown on coverslips were
stimulated with DF3, fixed with 2% PFA, and permeabilized with 0.1%
Triton-X in PBS. Cells were blocked in 3% BSA (in PBS) and
incubated with primary antibodies at a 1:100 dilution in blocking
buffer for 1 h. To detect the proximity between two proteins,
complementary secondary probes (PLUS and MINUS) binding the
primaries raised in different species were added to cells at a 1:5
dilution in blocking buffer for 60 min at 37 °C. Subsequent detection
of the proximity of bound probes was performed with an in situ PLA
detection kit (Olink), as per the manufacturer’s instructions. Cells
were imaged with an LSM510 META confocal microscope. PLA
signals represented by individual punctas were quantified using
Omero.49 Statistical differences were computed using a Student’s t test.
Nucleofection of siRNAs. RBL-2H3 cells were transfected with
Qiagen Flexi Tube siRNA for rat SHIP, SHP-1, and SHP-2 or Lyn
SmartPool siRNA from Dharmacon. The Amaxa Nucleofector and
Cell Line Nucleofector kit T (Lonza Cologne GmbH) were utilized
according to the manufacturer’s protocol. Cells were transfected with
0.25−0.5 μg of siRNA per 1 million cells and plated in regular growth
medium. The cultures were allowed to rest for 24 h before
experiments were performed and the efficiency of knockdown was
determined via immunoblot analyses.
Computational Modeling of Structures and Ligand−
Receptor Binding. Structural models of ligand-induced receptor
aggregates were built using the motif binding geometry method,50
homology modeling, and molecular dynamics. A model for IgE bound
simultaneously to FcεRIα and DNP was constructed on the basis of
available structures [Protein Data Bank (PDB) entries 1OAU, 2VWE,
1O0V, and 1F6A] and knowledge of how these molecules interact.
The structure of the trimeric foldon is known (PDB entry 1RFO). The
structure of the linker peptide used to connect the foldon to DNP was
determined using an algorithm for modeling protein loops with fixed
ends.51 Our model for the interaction of DF3 with cell-surface IgE was
formulated in terms of local rules and simulated as described
previously.8 A novel aspect of the model is a negative application
condition that prohibits interactions between aggregates containing
more than a threshold number of receptors. Additional details about
the model and a description of how parameters were estimated on the
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